Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CDK4 | P11802 | 5/20 | 0.65 |
| ▸ | CCND1 | P24385 | 5/20 | 0.65 |
| ▸ | GOT1 | P17174 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925563 | 0.85 | MTNR1A (0.63) | TRPV1MEN1KMT2ALMNAMAPT | |
| SCHEMBL797879 | 0.83 | MEN1 (0.76) | TRPV1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4331421 | 0.82 | MEN1 (1.00) | TRPV1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL23925488 | 0.82 | MEN1 (0.82) | TRPV1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14082661 | 0.81 | TRPV1 (0.73) | TRPV1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15047821 | 0.79 | MEN1 (0.82) | TRPV1MEN1KMT2ANPC1RAB9A | |
| Cyanide SCHEMBL31484737 | 0.79 | MEN1 (0.92) | TRPV1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2944294 | 0.79 | CYP19A1 (0.70) | TRPV1MEN1KMT2A | |
| SCHEMBL1972441 | 0.79 | USP2 (0.77) | TRPV1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29991148 | 0.79 | USP2 (0.77) | TRPV1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| CN-101321749-A | Novel vinylogous acid derivatives | HOFFMANN LA ROCHE (CH) | 2008-12-10 | — | — | CN | disclosed |
| EP-1957483-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063010-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
| US-6852734-B2 | Indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20040058963-A1 | Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1284266-A1 | NOVEL INDOLE DERIVATIVES EXHIBITING CHYMASE-INHIBITORY ACTIVITIES AND PROCESS FOR PREPARATION THEREOF | MEIJI SEIKA KAISHA LTD. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129421-A1 | Vinylogous acid derivatives | CMA1, TPSG1, TPSAB1 | TRPV1 794/4885MEN1 713/4885KMT2A 2349/4885 |
| US-20040058963-A1 | Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof | CMA1, TPSD1, IDO1 | TRPV1 3038/4885MEN1 2387/4885KMT2A 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.